Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF
Get informed when a big investor buys or sells
+ FollowMarket Cap$66.94B
Close$
$0.95
61.3% downside
Current Fair Value
61.3% downsideOvervalued by 61.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $66.94 Billion |
|---|---|
| Enterprise Value | $93.77 Billion |
| Dividend Yield | $0.06 (1.63%) |
| Earnings per Share | $1.26 |
| Beta | 0.44 |
| Outstanding Shares | 2,639,554,000 |
Return
| Return on Equity | 10.33% |
|---|---|
| Return on Assets | 4.01% |
| Return on Invested Capital | 4.81% |
Valuation & Multiples
| P/E Ratio | 18.66 |
|---|---|
| PEG | 22.99 |
| Price to Sales | 0.11 |
| Price to Book Ratio | 0.1 |
| Enterprise Value to Revenue | 1.52 |
| Enterprise Value to EBIT | 22.46 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.43 |
| Debt to Equity | 0.83 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.53 B
Average shareholder expectationNext Earnings Call
Expected Date
March 29, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.63 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
40,603 employees
CEO: Yi Liu Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercializ...